Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies
In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al.1 compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervic...
Gespeichert in:
| Veröffentlicht in: | Med (New York, N.Y. : Online) N.Y. : Online), 2024-06, Vol.5 (6), p.487-489 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 489 |
|---|---|
| container_issue | 6 |
| container_start_page | 487 |
| container_title | Med (New York, N.Y. : Online) |
| container_volume | 5 |
| creator | How, Jeffrey A. Jazaeri, Amir A. |
| description | In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al.1 compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.
In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al. compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival. |
| doi_str_mv | 10.1016/j.medj.2024.05.001 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3068752019</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2666634024002058</els_id><sourcerecordid>3068752019</sourcerecordid><originalsourceid>FETCH-LOGICAL-c307t-fefb46eae0abdf45d4f181863f9c05da4e44f30a4fcf8d3c53926af63785b1d13</originalsourceid><addsrcrecordid>eNp9kM1uEzEUhS1ERau2L8ACeclmhuvxzziITVUFiKjopl10ZTn2dXA0P8GeRMrb16OUilVXvra_c6T7EfKRQc2AqS_buke_rRtoRA2yBmDvyEWjlKoUF_D-v_mcXOe8BYBGMs4WzQdyzrVudavkBcFV3--HcfqDye6ONA60G53tuiO1_mAHh546TIdY3qib7-krXQ0TbpKd4rChv5ZPv-8fltUN0yU8jbS3g91gj8NE81Qg3ETMV-Qs2C7j9ct5SR6_Lx9uf1Z39z9Wtzd3lePQTlXAsBYKLYJd-yCkF4FpphUPCwfSW4FCBA5WBBe0507yRaNsULzVcs0845fk86l3l8a_e8yT6WN22HV2wHGfDQelW9kAWxS0OaEujTknDGaXYm_T0TAws2GzNbNhMxs2IE0xXEKfXvr36_L5GvnnswDfTgCWLQ8Rk8ku4qwxJnST8WN8q_8Z6ueNag</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3068752019</pqid></control><display><type>article</type><title>Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>How, Jeffrey A. ; Jazaeri, Amir A.</creator><creatorcontrib>How, Jeffrey A. ; Jazaeri, Amir A.</creatorcontrib><description>In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al.1 compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.
In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al. compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.</description><identifier>ISSN: 2666-6340</identifier><identifier>EISSN: 2666-6340</identifier><identifier>DOI: 10.1016/j.medj.2024.05.001</identifier><identifier>PMID: 38878765</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antibodies, Monoclonal, Humanized - therapeutic use ; Chemoradiotherapy - methods ; Female ; Humans ; Immune Checkpoint Inhibitors - pharmacology ; Immune Checkpoint Inhibitors - therapeutic use ; Immunotherapy - methods ; Randomized Controlled Trials as Topic ; Uterine Cervical Neoplasms - drug therapy ; Uterine Cervical Neoplasms - pathology ; Uterine Cervical Neoplasms - therapy</subject><ispartof>Med (New York, N.Y. : Online), 2024-06, Vol.5 (6), p.487-489</ispartof><rights>2024 Elsevier Inc.</rights><rights>Copyright © 2024 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c307t-fefb46eae0abdf45d4f181863f9c05da4e44f30a4fcf8d3c53926af63785b1d13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38878765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>How, Jeffrey A.</creatorcontrib><creatorcontrib>Jazaeri, Amir A.</creatorcontrib><title>Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies</title><title>Med (New York, N.Y. : Online)</title><addtitle>Med</addtitle><description>In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al.1 compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.
In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al. compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.</description><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Chemoradiotherapy - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Immune Checkpoint Inhibitors - pharmacology</subject><subject>Immune Checkpoint Inhibitors - therapeutic use</subject><subject>Immunotherapy - methods</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Uterine Cervical Neoplasms - drug therapy</subject><subject>Uterine Cervical Neoplasms - pathology</subject><subject>Uterine Cervical Neoplasms - therapy</subject><issn>2666-6340</issn><issn>2666-6340</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1uEzEUhS1ERau2L8ACeclmhuvxzziITVUFiKjopl10ZTn2dXA0P8GeRMrb16OUilVXvra_c6T7EfKRQc2AqS_buke_rRtoRA2yBmDvyEWjlKoUF_D-v_mcXOe8BYBGMs4WzQdyzrVudavkBcFV3--HcfqDye6ONA60G53tuiO1_mAHh546TIdY3qib7-krXQ0TbpKd4rChv5ZPv-8fltUN0yU8jbS3g91gj8NE81Qg3ETMV-Qs2C7j9ct5SR6_Lx9uf1Z39z9Wtzd3lePQTlXAsBYKLYJd-yCkF4FpphUPCwfSW4FCBA5WBBe0507yRaNsULzVcs0845fk86l3l8a_e8yT6WN22HV2wHGfDQelW9kAWxS0OaEujTknDGaXYm_T0TAws2GzNbNhMxs2IE0xXEKfXvr36_L5GvnnswDfTgCWLQ8Rk8ku4qwxJnST8WN8q_8Z6ueNag</recordid><startdate>20240614</startdate><enddate>20240614</enddate><creator>How, Jeffrey A.</creator><creator>Jazaeri, Amir A.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240614</creationdate><title>Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies</title><author>How, Jeffrey A. ; Jazaeri, Amir A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c307t-fefb46eae0abdf45d4f181863f9c05da4e44f30a4fcf8d3c53926af63785b1d13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Chemoradiotherapy - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Immune Checkpoint Inhibitors - pharmacology</topic><topic>Immune Checkpoint Inhibitors - therapeutic use</topic><topic>Immunotherapy - methods</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Uterine Cervical Neoplasms - drug therapy</topic><topic>Uterine Cervical Neoplasms - pathology</topic><topic>Uterine Cervical Neoplasms - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>How, Jeffrey A.</creatorcontrib><creatorcontrib>Jazaeri, Amir A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Med (New York, N.Y. : Online)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>How, Jeffrey A.</au><au>Jazaeri, Amir A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies</atitle><jtitle>Med (New York, N.Y. : Online)</jtitle><addtitle>Med</addtitle><date>2024-06-14</date><risdate>2024</risdate><volume>5</volume><issue>6</issue><spage>487</spage><epage>489</epage><pages>487-489</pages><issn>2666-6340</issn><eissn>2666-6340</eissn><abstract>In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al.1 compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.
In locally advanced cervical cancer (LACC), the benefit of PD-1 blockade was unknown. In KEYNOTE-A18, Lorusso et al. compared the efficacy and safety of adding pembrolizumab to chemoradiation in LACC and demonstrated favorable outcomes. Given multiple approved indications of pembrolizumab in cervical cancer, strategies for optimal integration into management will be needed to maximize overall survival.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>38878765</pmid><doi>10.1016/j.medj.2024.05.001</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2666-6340 |
| ispartof | Med (New York, N.Y. : Online), 2024-06, Vol.5 (6), p.487-489 |
| issn | 2666-6340 2666-6340 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3068752019 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antibodies, Monoclonal, Humanized - therapeutic use Chemoradiotherapy - methods Female Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunotherapy - methods Randomized Controlled Trials as Topic Uterine Cervical Neoplasms - drug therapy Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - therapy |
| title | Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T01%3A33%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunotherapy%20in%20locally%20advanced%20cervical%20cancer:%20Integrating%20KEYNOTE-A18%20into%20management%20strategies&rft.jtitle=Med%20(New%20York,%20N.Y.%20:%20Online)&rft.au=How,%20Jeffrey%20A.&rft.date=2024-06-14&rft.volume=5&rft.issue=6&rft.spage=487&rft.epage=489&rft.pages=487-489&rft.issn=2666-6340&rft.eissn=2666-6340&rft_id=info:doi/10.1016/j.medj.2024.05.001&rft_dat=%3Cproquest_cross%3E3068752019%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3068752019&rft_id=info:pmid/38878765&rft_els_id=S2666634024002058&rfr_iscdi=true |